摘要
抗凋亡蛋白bcl-2是内在凋亡途径的关键调节因子,常在血液系统恶性肿瘤细胞中过度表达,靶向该凋亡途径的小分子抑制剂维奈克拉在治疗慢性淋巴细胞白血病和小淋巴细胞淋巴瘤中显示出很好的疗效。对于高龄或因合并疾病不适合接受强诱导化疗的急性髓系白血病的患者也能显著改善其生存和预后,但在维奈克拉治疗过程中部分患者逐渐出现耐药,影响药物治疗效果。文章就维奈克拉在血液系统恶性肿瘤中的作用机制、治疗进展及耐药机制进行综述。
The anti-apoptotic protein bcl-2,a key regulator of the intrinsic apoptotic pathway,is frequently overexpressed in cells of hematologic malignancies,and the small molecule inhibitor venetoclax that targets this apoptotic pathway has shown promising efficacy in the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma.The survival and prognosis of patients with acute myeloid leukemia who are of advanced age or who are unsuitable for strong induction chemotherapy because of comorbidities also have significantly improved,but some patients develop progressive drug resistance during the course of venetoclax treatment,which affects the efficacy of medical therapy.This article reviews the action mechanism,therapeutic progress and resistance mechanism of venetoclax in hematologic malignancies.
作者
张乔语
杜新
Zhang Qiaoyu;Du Xin(Department of Hematology,the Second People's Hospital of Shenzhen,Shenzhen 518035,China)
出处
《白血病．淋巴瘤》
CAS
2023年第4期253-256,共4页
Journal of Leukemia & Lymphoma
关键词
血液肿瘤
维奈克拉
耐药性
治疗结果
Hematologic neoplasms
Venetoclax
Drug tolerance
Treatment outcome
